BioCentury | Jan 25, 2016
Company News

Biotie, Acorda deal

...an oral selective adenosine A2A receptor (ADORA2A) antagonist that is in Phase III testing; and SYN120...
...by year end 2018 and expects data this year from a Phase IIa trial of SYN120...
BioCentury | Jan 20, 2016
Top Story

Acorda adds to PD portfolio with Biotie takeout

...in cash (see BioCentury Extra, Sept. 24, 2014) . The Biotie deal also gives Acorda SYN120...
...and serotonin (5-HT2A) receptor. Acorda expects data by YE16 from a Phase IIa study of SYN120...
BioCentury | Jan 19, 2015
Clinical News

SYN120: Phase IIa started

...Parkinson Study Group began the double-blind, placebo-controlled, U.S. Phase IIa SYNAPSE trial to evaluate once-daily SYN120...
...mg SYN120 the first week, 50 mg SYN120 in the second week and 100 mg SYN120...
...Michael J. Fox Foundation is funding the trial. Biotie Therapies Corp. (HSE:BTH1V), Turku, Finland Product: SYN120...
BioCentury | Mar 10, 2014
Company News

Biotie Therapeutics Corp., Neurelis deal

...see BioCentury, June 10, 2013 & Oct. 7, 2013). Biotie also said it will develop SYN120...
...at year end. Biotie did not respond in time of publication. Biotie gained rights to SYN120...
...AG , which had rights from Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) to develop and commercialize SYN120...
BioCentury | Oct 7, 2013
Company News

Biotie neurology, hepatic news

...vascular adhesion protein-1 (VAP-1; SSAO). Biotie also said that discussions for a potential partnership for SYN120...
...said Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) declined to exercise its option to regain rights to SYN120...
BioCentury | Apr 8, 2013
Product Development

AD(ing) an antagonist

...to say how their molecule differs from the GSK compound. Biotie Therapies Corp. is developing SYN120...
...where both types of disturbance frequently overlap," VP of Clinical Development Uwe Meya told BioCentury. SYN120...
...discussions with several pharmaceutical companies about a potential partnership" involving SYN120. Roche had originally discovered SYN120...
BioCentury | Jul 2, 2012
Finance

Highlights of weekly biotech stock moves

...its option to regain rights to cognitive impairment product SYN120 , citing "strategic portfolio reasons." SYN120...
BioCentury | Jul 2, 2012
Company News

Biotie, Roche deal

...Biotie said Roche declined to exercise its option to regain rights to cognitive impairment product SYN120...
...is confident it will find a partner. Details were not disclosed. Biotie gained rights to SYN120...
...acquisition of Synosia Therapeutics AG , which had rights from Roche to develop and commercialize SYN120...
BioCentury | Jun 27, 2012
Company News

Roche declines SYN120 option

...Roche (SIX:ROG; OTCQX:RHHBY) declined to exercise its option to regain rights to cognitive impairment product SYN120...
...is confident it will find a partner. Details were not disclosed. Biotie gained rights to SYN120...
...acquisition of Synosia Therapeutics AG , which had rights from Roche to develop and commercialize SYN120...
BioCentury | Mar 12, 2012
Clinical News

SYN120: Phase I data

...5-HT6 receptor occupancy that are expected for efficacy can be achieved with doses of oral SYN120...
...disclosed. Levels of 5-HT6 receptor occupancy were measured by PET imaging. Biotie gained rights to SYN120...
...acquisition of Synosia Therapeutics AG , which had rights from Roche to develop and commercialize SYN120...
Items per page:
1 - 10 of 16